Impact of systemic Immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer
Urol Oncol. 2021 Jun 8:S1078-1439(21)00208-8. doi: 10.1016/j.urolonc.2021.05.002. Online ahead of print.ABSTRACTPURPOSE: To evaluate the predictive and prognostic value of the Systemic Immune-inflammation Index (SII) in a large cohort of patients treated with radical prostatectomy (RP) for clinically non-metastatic prostate cancer (PCa).METHODS: We retrospectively analyzed our multicenter database comprising 6,039 consecutive patients. The optimal preoperative SII cut-off value was assessed with the Youden index calculated on a time-dependent receiver operating characteristic (ROC) curve. Logistic regression and Cox regres...
Source: Urologic Oncology - June 12, 2021 Category: Urology & Nephrology Authors: Pawel Rajwa Victor M Schuettfort David D'Andrea Fahad Quhal Keiichiro Mori Satoshi Katayama Ekaterina Laukhtina Benjamin Pradere Reza Sari Motlagh Hadi Mostafaei Nico C Grossmann Nicolai Huebner Andreas Aulitzky Dong-Ho Mun Alberto Briganti Pierre I Karak Source Type: research

Low conflict and high satisfaction: Decisional outcomes after attending a combined clinic to choose between robotic prostatectomy and radiotherapy for prostate cancer
This study assessed decisional outcomes in men deciding between RARP or radiotherapy treatment before and after attending a LPC combined clinic (CC).METHODS: Quantitative longitudinal data were collected from 52 men who attended a LPC CC, where they saw both a urologist and radiation oncologist. Patients completed questionnaires assessing involvement in decision-making, decisional conflict, satisfaction and regret before and after the CC, three months, six months and 12 months post-treatment. Urologists and radiation oncologists also reported their perceptions regarding patients' suitability for, openness to, perceived pre...
Source: Urologic Oncology - June 12, 2021 Category: Urology & Nephrology Authors: Allan 'Ben' Smith Orlando Rincones Pascal Mancuso Mark Sidhom Karen Wong Megan Berry Dion Forstner Diana Ngo Lesley Bokey Afaf Girgis Source Type: research

"Collecting duct carcinoma of the kidney: diagnosis and implications for management"
Urol Oncol. 2021 Jun 8:S1078-1439(21)00204-0. doi: 10.1016/j.urolonc.2021.04.041. Online ahead of print.ABSTRACTCollecting duct carcinoma of the kidney is a rare and aggressive subtype of renal cell carcinoma (RCC) arising from the distal convoluted tubules. At the time of diagnosis, patients are more frequently symptomatic, with advanced locoregional stage, and have metastatic disease. The 2016 WHO Classification of Tumours of the Urinary System defined diagnostic criteria for this entity. However, the diagnostic features continue to evolve, with typical, but not entirely specific, histologic and immunophenotypic characte...
Source: Urologic Oncology - June 12, 2021 Category: Urology & Nephrology Authors: Gerardo Cabanillas Diego Montoya-Cerrillo Oleksandr N Kryvenko Sumanta K Pal Javier A Arias-Stella Source Type: research

Clinical and radiological findings for small renal masses under active surveillance
CONCLUSION: Active surveillance is a feasible option for management of SRMs in selected patients without jeopardizing oncological safety. In our series, no clinical or radiological characteristics for predicting tumour growth were found.PMID:34116937 | DOI:10.1016/j.urolonc.2021.04.010 (Source: Urologic Oncology)
Source: Urologic Oncology - June 12, 2021 Category: Urology & Nephrology Authors: Tarek Ajami Carmen Sebastia Daniel Corominas Maria Jose Ribal Carlos Nicolau Antonio Alcaraz Mireia Musquera Source Type: research

Tumors masquerading as type 2 papillary renal cell carcinoma: pathologists' ever-expanding differential diagnosis for a heterogeneous group of entities
Urol Oncol. 2021 Jun 8:S1078-1439(21)00206-4. doi: 10.1016/j.urolonc.2021.04.043. Online ahead of print.ABSTRACTAlthough papillary renal cell carcinoma has historically been classified as either type 1 or type 2, data from The Cancer Genome Atlas (TCGA) has demonstrated significant genomic heterogeneity in tumors classified as "type 2 papillary renal cell carcinoma" (T2PRCC). Papillary renal cell carcinoma is expected to have a favorable clinical course compared to clear cell renal cell carcinoma (CCRCC). However, tumors with poor outcome more similar to CCRCC were included in the T2PRCC cohort studied by the TCG...
Source: Urologic Oncology - June 12, 2021 Category: Urology & Nephrology Authors: Alexander S Taylor Stephanie L Skala Source Type: research

Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN study
CONCLUSION: Our data suggest that lower MCS at AS enrollment using patient-reported outcomes was negatively associated with the first repeat protocol biopsy compliance. Our study may support the availability of a simple questionnaire to extract non-compliance.PMID:34112576 | DOI:10.1016/j.urolonc.2021.05.003 (Source: Urologic Oncology)
Source: Urologic Oncology - June 11, 2021 Category: Urology & Nephrology Authors: Yoichiro Tohi Takuma Kato Akira Yokomizo Koji Mitsuzuka Ryotaro Tomida Junichi Inokuchi Ryuji Matsumoto Toshihiro Saito Hiroshi Sasaki Koji Inoue Hidefumi Kinoshita Hiroshi Fukuhara Satoru Maruyama Shinichi Sakamoto Toshiki Tanikawa Shin Egawa Haruhiko Ic Source Type: research

Clinicopathological significance and prognostic value of cancer-associated fibroblasts in prostate cancer patients
CONCLUSION: In summary, our study uncovered the clinicopathological significance and potential mechanism of CAFs and indicated that CAFs may be a useful prognostic biomarker in PCa.PMID:34112577 | DOI:10.1016/j.urolonc.2021.05.004 (Source: Urologic Oncology)
Source: Urologic Oncology - June 11, 2021 Category: Urology & Nephrology Authors: Zhenyu Wu Juanyi Shi Cong Lai Kaiwen Li Kuiqing Li Zhuohang Li Zhuang Tang Cheng Liu Kewei Xu Source Type: research

Urologic oncology randomized controlled trials are frequently fragile - A review of the urology literature
We examined the correlation of FI with sample size and P-value.RESULTS: We identified 216 RCT's, 79 were eligible for analysis. Median FI was 3.0 (2.5, 6.0). One hundred and forty-six (89.6%) outcomes from 72 (94.7%) RCT's had a FI lower than 10 and 6 (3.7%) outcomes from 6 (7.9%) RCT's had a FI = 0. There was no statistically significant difference in FI between different types of outcomes. There was a modest correlation between the FI and the sample size (rs 0.50, P
Source: Urologic Oncology - June 9, 2021 Category: Urology & Nephrology Authors: Leon Chertin Irina Burman Miki Haifler Source Type: research

Clinical characteristics of renal cell carcinoma in patients under the age of 40
CONCLUSION: Young RCC patients had a higher proportion of female gender, chromophobe histology, and favorable tumor characteristics. Partial nephrectomy has seen a dramatic increase in application regardless of age while percutaneous ablation increased only in the conventional cohort.PMID:34103226 | DOI:10.1016/j.urolonc.2021.04.008 (Source: Urologic Oncology)
Source: Urologic Oncology - June 9, 2021 Category: Urology & Nephrology Authors: Brian Douglas Facundo Davaro Allison May Sameer Siddiqui Zachary Hamilton Source Type: research

Urologic oncology randomized controlled trials are frequently fragile - A review of the urology literature
We examined the correlation of FI with sample size and P-value.RESULTS: We identified 216 RCT's, 79 were eligible for analysis. Median FI was 3.0 (2.5, 6.0). One hundred and forty-six (89.6%) outcomes from 72 (94.7%) RCT's had a FI lower than 10 and 6 (3.7%) outcomes from 6 (7.9%) RCT's had a FI = 0. There was no statistically significant difference in FI between different types of outcomes. There was a modest correlation between the FI and the sample size (rs 0.50, P
Source: Urologic Oncology - June 9, 2021 Category: Urology & Nephrology Authors: Leon Chertin Irina Burman Miki Haifler Source Type: research

Clinical characteristics of renal cell carcinoma in patients under the age of 40
CONCLUSION: Young RCC patients had a higher proportion of female gender, chromophobe histology, and favorable tumor characteristics. Partial nephrectomy has seen a dramatic increase in application regardless of age while percutaneous ablation increased only in the conventional cohort.PMID:34103226 | DOI:10.1016/j.urolonc.2021.04.008 (Source: Urologic Oncology)
Source: Urologic Oncology - June 9, 2021 Category: Urology & Nephrology Authors: Brian Douglas Facundo Davaro Allison May Sameer Siddiqui Zachary Hamilton Source Type: research

Urologic oncology randomized controlled trials are frequently fragile - A review of the urology literature
We examined the correlation of FI with sample size and P-value.RESULTS: We identified 216 RCT's, 79 were eligible for analysis. Median FI was 3.0 (2.5, 6.0). One hundred and forty-six (89.6%) outcomes from 72 (94.7%) RCT's had a FI lower than 10 and 6 (3.7%) outcomes from 6 (7.9%) RCT's had a FI = 0. There was no statistically significant difference in FI between different types of outcomes. There was a modest correlation between the FI and the sample size (rs 0.50, P
Source: Urologic Oncology - June 9, 2021 Category: Urology & Nephrology Authors: Leon Chertin Irina Burman Miki Haifler Source Type: research

Clinical characteristics of renal cell carcinoma in patients under the age of 40
CONCLUSION: Young RCC patients had a higher proportion of female gender, chromophobe histology, and favorable tumor characteristics. Partial nephrectomy has seen a dramatic increase in application regardless of age while percutaneous ablation increased only in the conventional cohort.PMID:34103226 | DOI:10.1016/j.urolonc.2021.04.008 (Source: Urologic Oncology)
Source: Urologic Oncology - June 9, 2021 Category: Urology & Nephrology Authors: Brian Douglas Facundo Davaro Allison May Sameer Siddiqui Zachary Hamilton Source Type: research

Radium-223 in patients with prostate specific antigen (PSA) progression and without clinical metastases following maximal local therapy: A pilot study
CONCLUSIONS: Radium-223 in patients with PSA relapse following maximal local treatment without clinical metastases is safe. However, the clinical benefit of Ra-223 in this setting is doubtful as significant oncological benefit is lacking.PMID:34099385 | DOI:10.1016/j.urolonc.2021.04.034 (Source: Urologic Oncology)
Source: Urologic Oncology - June 8, 2021 Category: Urology & Nephrology Authors: Lorenzo Tosco Ga ëtan Devos Laura Schillebeeckx Steven Pans Karolien Goffin Wouter Everaerts Hendrik Van Poppel Steven Joniau Source Type: research

Radium-223 in patients with prostate specific antigen (PSA) progression and without clinical metastases following maximal local therapy: A pilot study
CONCLUSIONS: Radium-223 in patients with PSA relapse following maximal local treatment without clinical metastases is safe. However, the clinical benefit of Ra-223 in this setting is doubtful as significant oncological benefit is lacking.PMID:34099385 | DOI:10.1016/j.urolonc.2021.04.034 (Source: Urologic Oncology)
Source: Urologic Oncology - June 8, 2021 Category: Urology & Nephrology Authors: Lorenzo Tosco Ga ëtan Devos Laura Schillebeeckx Steven Pans Karolien Goffin Wouter Everaerts Hendrik Van Poppel Steven Joniau Source Type: research

The robotic approach improves the outcomes of ERAS protocol after radical cystectomy: A prospective case-control analysis
Urol Oncol. 2021 Jun 3:S1078-1439(21)00172-1. doi: 10.1016/j.urolonc.2021.04.015. Online ahead of print.ABSTRACTBACKGROUND: Minimally-invasive approach is one of the mainstays of Enhanced Recovery After Surgery (ERAS) pathways. Robot-assisted radical cystectomy (RARC) introduction has reduced the surgical burden on patient's recovery. Accordingly, ERAS protocol benefits may be more striking in RARC patients. We evaluated the impact of surgical approach on perioperative outcomes, Fast Track (FT) recovery steps and Trifecta success rates in patients undergoing RC followed by FT protocol.MATERIALS AND METHODS: We considered 1...
Source: Urologic Oncology - June 7, 2021 Category: Urology & Nephrology Authors: Riccardo Schiavina Matteo Droghetti Lorenzo Bianchi Amelio Ercolino Francesco Chessa Carlo Casablanca Pietro Piazza Angelo Mottaran Dario Recenti Marco Salvador Crescenzo Cacciapuoti Sara Boschi Marco Giampaoli Alessandro Bertaccini Daniele Romagnoli Ange Source Type: research

A contemporary guide to chromosomal copy number profiling in the diagnosis of renal cell carcinoma
Urol Oncol. 2021 Jun 3:S1078-1439(21)00205-2. doi: 10.1016/j.urolonc.2021.04.042. Online ahead of print.ABSTRACTThe routine clinical implementation of molecular methods other than fluorescence in situ hybridization in the evaluation of renal neoplasia is currently limited, as the current standard of care primarily involves a combination of morphologic and immunophenotypic analysis of such tumors. Amongst various molecular techniques, global copy number profiling using single nucleotide polymorphism-based microarrays, colloquially referred to as SNP-arrays, is being increasingly utilized to profile renal tumors, as several ...
Source: Urologic Oncology - June 7, 2021 Category: Urology & Nephrology Authors: Sounak Gupta William R Sukov Chad M Vanderbilt Wei Shen Loren Herrera-Hernandez Christine M Lohse R Houston Thompson Stephen A Boorjian Bradley C Leibovich Rafael E Jimenez John C Cheville Source Type: research

Telemedicine in management of genitourinary malignancies: Patient and physician perspectives
CONCLUSION: We observed high levels of patient and physician satisfaction for telemedicine visits for management of genitourinary malignancies. Technological barriers were encountered by 9% of patients and were associated with decreased satisfaction.PMID:34092480 | DOI:10.1016/j.urolonc.2021.04.003 (Source: Urologic Oncology)
Source: Urologic Oncology - June 7, 2021 Category: Urology & Nephrology Authors: Ezra J Margolin Luis A Pina Martina Caleb H Miles Sven Wenske James M McKiernan G Joel DeCastro Elias S Hyams Charles G Drake Emerson A Lim Mark N Stein Israel Deutsch Christopher B Anderson Source Type: research

Contemporary analysis of the effect of marital status on survival in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: A population-based study
Urol Oncol. 2021 Jun 4:S1078-1439(21)00197-6. doi: 10.1016/j.urolonc.2021.04.040. Online ahead of print.ABSTRACTPURPOSE: Unmarried status is an established risk factor for worse cancer control outcomes in various malignancies. Moreover, several investigators observed worse outcomes in unmarried males, but not in females. This concept has not been tested in upper tract urothelial carcinoma and represents the topic of the study.METHODS: Within Surveillance, Epidemiology and End Results database (2004-2016), we identified 8833 non-metastatic upper tract urothelial carcinoma patients treated with radical nephroureterectomy (52...
Source: Urologic Oncology - June 7, 2021 Category: Urology & Nephrology Authors: Claudia Coll à Ruvolo Luigi Nocera Franziska L Stolzenbach Mike Wenzel Christoph W ürnschimmel Ferdinando Fusco Alessandro Palmieri Zhe Tian Shahrokh F Shariat Fred Saad Alberto Briganti Ciro Imbimbo Vincenzo Mirone Pierre I Karakiewicz Source Type: research

Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG
Urol Oncol. 2021 Jun 3:S1078-1439(21)00134-4. doi: 10.1016/j.urolonc.2021.03.024. Online ahead of print.ABSTRACTINTRODUCTION: Repeat BCG induction remains an option for select non-muscle invasive bladder cancer (NMIBC) patients who fail initial therapy. Alternative salvage intravesical regimens such as Gemcitabine and Docetaxel (Gem/Doce) have been investigated. We aimed to compare the efficacy BCG plus interferon a-2b (BCG/IFN) and Gem/Doce in patients with recurrent NMIBC after a single prior BCG course.METHODS: The National Phase II BCG/IFN trial database and multi-institutional Gem/Doce database were queried for patien...
Source: Urologic Oncology - June 7, 2021 Category: Urology & Nephrology Authors: Ryan L Steinberg Vignesh T Packiam Lewis J Thomas Nathan Brooks Andrew Vitale Sarah L Mott Trafford Crump Jonathan Wang William C DeWolf Donald L Lamm Max Kates M Eric Hyndman Ashish M Kamat Trinity J Bivalacqua Kenneth G Nepple Michael A O'Donnell Source Type: research

A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer
Urol Oncol. 2021 Jun 4:S1078-1439(21)00194-0. doi: 10.1016/j.urolonc.2021.04.038. Online ahead of print.ABSTRACTThe diagnosis, evaluation and management of patients with renal cell carcinoma has transformed in the 21st century. Utilizing biological discoveries and technological advances, the field has moved from blunt surgical and largely ineffective medical treatments, to nuanced and fine-tuned approaches based on biology, extent of disease and patient preferences. In this review we will summarize the last 25 years of progress in kidney cancer.PMID:34092483 | DOI:10.1016/j.urolonc.2021.04.038 (Source: Urologic Oncology)
Source: Urologic Oncology - June 7, 2021 Category: Urology & Nephrology Authors: Daniel M Geynisman Jodi K Maranchie Mark W Ball Gennady Bratslavsky Eric A Singer Source Type: research

Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center
CONCLUSION: Oncological outcomes after RP can be excellent for individuals with favorable CaP characteristics, also after 20 years of follow up.PMID:34092484 | DOI:10.1016/j.urolonc.2021.04.031 (Source: Urologic Oncology)
Source: Urologic Oncology - June 7, 2021 Category: Urology & Nephrology Authors: Christoph W ürnschimmel Mike Wenzel Nuowei Wang Zhe Tian Pierre I Karakiewicz Markus Graefen Hartwig Huland Derya Tilki Source Type: research

Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma
CONCLUSIONS: The present study confirms over-expression of CA9 in UC and for the first time shows a correlation with molecular subtypes. However, CA9 expression showed no association with the outcome of patients with muscle invasive bladder cancer and inhibition of CA9 did not lead to a consistent inhibition of tumor growth. Based on these data, CA9 exhibits a role neither as a predictive or prognostic marker nor as a therapeutic target in invasive UC.PMID:34083096 | DOI:10.1016/j.urolonc.2021.04.011 (Source: Urologic Oncology)
Source: Urologic Oncology - June 4, 2021 Category: Urology & Nephrology Authors: Tilman Todenh öfer Ewan A Gibb Roland Seiler Alireza Kamyabi J örg Hennenlotter Paul McDonald Igor Moskalev Craig Stewart Jian Gao Ladan Fazli Shoukat Dedhar Arnulf Stenzl Htoo Zarni Oo Peter C Black Source Type: research

Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma
CONCLUSIONS: The present study confirms over-expression of CA9 in UC and for the first time shows a correlation with molecular subtypes. However, CA9 expression showed no association with the outcome of patients with muscle invasive bladder cancer and inhibition of CA9 did not lead to a consistent inhibition of tumor growth. Based on these data, CA9 exhibits a role neither as a predictive or prognostic marker nor as a therapeutic target in invasive UC.PMID:34083096 | DOI:10.1016/j.urolonc.2021.04.011 (Source: Urologic Oncology)
Source: Urologic Oncology - June 4, 2021 Category: Urology & Nephrology Authors: Tilman Todenh öfer Ewan A Gibb Roland Seiler Alireza Kamyabi J örg Hennenlotter Paul McDonald Igor Moskalev Craig Stewart Jian Gao Ladan Fazli Shoukat Dedhar Arnulf Stenzl Htoo Zarni Oo Peter C Black Source Type: research

Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma
CONCLUSIONS: The present study confirms over-expression of CA9 in UC and for the first time shows a correlation with molecular subtypes. However, CA9 expression showed no association with the outcome of patients with muscle invasive bladder cancer and inhibition of CA9 did not lead to a consistent inhibition of tumor growth. Based on these data, CA9 exhibits a role neither as a predictive or prognostic marker nor as a therapeutic target in invasive UC.PMID:34083096 | DOI:10.1016/j.urolonc.2021.04.011 (Source: Urologic Oncology)
Source: Urologic Oncology - June 4, 2021 Category: Urology & Nephrology Authors: Tilman Todenh öfer Ewan A Gibb Roland Seiler Alireza Kamyabi J örg Hennenlotter Paul McDonald Igor Moskalev Craig Stewart Jian Gao Ladan Fazli Shoukat Dedhar Arnulf Stenzl Htoo Zarni Oo Peter C Black Source Type: research

Best practices for assessing and reporting tobacco use in urology oncology practice and research
Urol Oncol. 2021 May 31:S1078-1439(21)00189-7. doi: 10.1016/j.urolonc.2021.04.033. Online ahead of print.ABSTRACTTobacco use is the cause of several urologic cancers. Persistent use after diagnosis is associated with worse cancer-specific, quality of life, and overall mortality outcomes. Cigarette smoking remains the most common form of tobacco use despite significant population-level decline over the past few decades. The burden of smoking-related urologic disease is under appreciated by urologists and patients which has resulted in gaps in clinical care and limitations to research progress. We sought to summarize evidenc...
Source: Urologic Oncology - June 3, 2021 Category: Urology & Nephrology Authors: Richard S Matulewicz Marc A Bjurlin Filipe Lf Carvalho Matthew Mossanen Omar El-Shahawy Source Type: research

Volume-outcome relationships for kidney cancer may be driven by disparities and patient risk
CONCLUSIONS: Surgeons and hospitals differ in regards to patient demographic and clinical factors. Barriers exist regarding access to high-volume care, and thus some volume-outcome trends may be driven predominantly by disparities and case mix.PMID:34078583 | DOI:10.1016/j.urolonc.2021.04.036 (Source: Urologic Oncology)
Source: Urologic Oncology - June 3, 2021 Category: Urology & Nephrology Authors: Julia J Wainger Joseph G Cheaib Hiten D Patel Mitchell M Huang Michael J Biles Meredith R Metcalf Joseph K Canner Nirmish Singla Bruce J Trock Mohamad E Allaf Phillip Pierorazio Source Type: research

Best practices for assessing and reporting tobacco use in urology oncology practice and research
Urol Oncol. 2021 May 31:S1078-1439(21)00189-7. doi: 10.1016/j.urolonc.2021.04.033. Online ahead of print.ABSTRACTTobacco use is the cause of several urologic cancers. Persistent use after diagnosis is associated with worse cancer-specific, quality of life, and overall mortality outcomes. Cigarette smoking remains the most common form of tobacco use despite significant population-level decline over the past few decades. The burden of smoking-related urologic disease is under appreciated by urologists and patients which has resulted in gaps in clinical care and limitations to research progress. We sought to summarize evidenc...
Source: Urologic Oncology - June 3, 2021 Category: Urology & Nephrology Authors: Richard S Matulewicz Marc A Bjurlin Filipe Lf Carvalho Matthew Mossanen Omar El-Shahawy Source Type: research

Volume-outcome relationships for kidney cancer may be driven by disparities and patient risk
CONCLUSIONS: Surgeons and hospitals differ in regards to patient demographic and clinical factors. Barriers exist regarding access to high-volume care, and thus some volume-outcome trends may be driven predominantly by disparities and case mix.PMID:34078583 | DOI:10.1016/j.urolonc.2021.04.036 (Source: Urologic Oncology)
Source: Urologic Oncology - June 3, 2021 Category: Urology & Nephrology Authors: Julia J Wainger Joseph G Cheaib Hiten D Patel Mitchell M Huang Michael J Biles Meredith R Metcalf Joseph K Canner Nirmish Singla Bruce J Trock Mohamad E Allaf Phillip Pierorazio Source Type: research

The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer
CONCLUSION: PET-CT is more accurate than CT-scan alone for preoperative LN staging in patients with BC.PMID:34059435 | DOI:10.1016/j.urolonc.2021.04.027 (Source: Urologic Oncology)
Source: Urologic Oncology - June 1, 2021 Category: Urology & Nephrology Authors: Mohamad Moussa Mohamad Abou Chakra Wajih Saad Athanasios Dellis Athanasios Papatsoris Source Type: research

The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer
CONCLUSION: PET-CT is more accurate than CT-scan alone for preoperative LN staging in patients with BC.PMID:34059435 | DOI:10.1016/j.urolonc.2021.04.027 (Source: Urologic Oncology)
Source: Urologic Oncology - June 1, 2021 Category: Urology & Nephrology Authors: Mohamad Moussa Mohamad Abou Chakra Wajih Saad Athanasios Dellis Athanasios Papatsoris Source Type: research

The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer
CONCLUSION: PET-CT is more accurate than CT-scan alone for preoperative LN staging in patients with BC.PMID:34059435 | DOI:10.1016/j.urolonc.2021.04.027 (Source: Urologic Oncology)
Source: Urologic Oncology - June 1, 2021 Category: Urology & Nephrology Authors: Mohamad Moussa Mohamad Abou Chakra Wajih Saad Athanasios Dellis Athanasios Papatsoris Source Type: research

Association of smoking status and recurrence of non-muscle invasive bladder cancer among patients managed with blue light cystoscopy
CONCLUSION: Smoking status was not significantly association with recurrence in a study of patients with predominantly high-risk recurrent NMIBC managed with photodynamic enhanced cystoscopy.PMID:34053856 | DOI:10.1016/j.urolonc.2021.04.028 (Source: Urologic Oncology)
Source: Urologic Oncology - May 31, 2021 Category: Urology & Nephrology Authors: Richard S Matulewicz Kourosh Ravvaz John A Weissert Sima Porten Gary D Steinberg Blue Light Cystoscopy with Cysview Registry Group Source Type: research

Adjuvant versus early salvage radiotherapy for prostate cancer patients: Time to move on
Urol Oncol. 2021 Mar 15:S1078-1439(21)00073-9. doi: 10.1016/j.urolonc.2021.02.012. Online ahead of print.ABSTRACTIn the management of prostate cancer , few treatments have caused as much controversy as adjuvant radiotherapy (ART) after radical prostatectomy in high-risk patients In the present article, we assess the exclusion and inclusion criteria of the 6 randomised trials and 5-year biochemical relapse-free survival and overall survival rates in order to identify the patient subgroups most likely to benefit from ART. We also evaluate treatment-related toxicity and the indications for androgen deprivation therapy . The m...
Source: Urologic Oncology - May 29, 2021 Category: Urology & Nephrology Authors: Carmen Gonz ález-San Segundo Felipe Cou ñago Alfonso G ómez-Iturriaga Source Type: research

Is hypofractionation acceptable for prostate bed radiotherapy?
Urol Oncol. 2021 Feb 23:S1078-1439(21)00060-0. doi: 10.1016/j.urolonc.2021.02.002. Online ahead of print.ABSTRACTApproximately 30% of patients who undergo radical prostatectomy for prostate cancer develop disease progression. The only potentially curative treatment in these patients is postoperative radiotherapy with or without hormonotherapy. One of the standards of care in nonsurgical patients is hypofractionated radiotherapy. However, the current evidence based is insufficient to define the optimal dose and fractionation schedule for postoperative radiotherapy. In this context, the aim of this editorial is to assess the...
Source: Urologic Oncology - May 29, 2021 Category: Urology & Nephrology Authors: Fernando L ópez Campos Gemma Sancho Pardo Xavier Maldonado Pijoan Thomas Zilli Felipe Cou ñago Lorenzo Asunci ón Hervás Morón Source Type: research

Prognostic value of preoperative albumin-to-fibrinogen ratio (AFR) in patients with bladder cancer treated with radical cystectomy
CONCLUSION: Preoperative low AFR is a prognostic biomarker for worse TTP, OS, CSS, and is independently associated with adverse tumor pathological features in BC patients undergoing RC. Our results suggest that especially patients with low AFR may be considered for neoadjuvant treatment.PMID:34049782 | DOI:10.1016/j.urolonc.2021.04.026 (Source: Urologic Oncology)
Source: Urologic Oncology - May 29, 2021 Category: Urology & Nephrology Authors: Francesco Claps Samarpit Rai Maria Carmen Mir Bas W G van Rhijn Giorgio Mazzon Laura Elizabeth Davis Crystal Lynn Valadon Tommaso Silvestri Michele Rizzo Murali Ankem Giovanni Liguori Antonio Celia Carlo Trombetta Nicola Pavan Source Type: research

Can quantitative analysis of multi-parametric MRI independently predict failure of focal salvage HIFU therapy in men with radio-recurrent prostate cancer?
CONCLUSIONS: One pharmacokinetic quantitative parameter based on DCE sequences seems to independently predict failure following focal salvage HIFU for radio-recurrent prostate cancer. This likely relates to the tumor microenvironment producing heat-sinks which counter the heating effect of HIFU. Further validation in larger datasets and evaluating mechanisms to reduce heat-sinks are required.PMID:34049783 | DOI:10.1016/j.urolonc.2021.04.017 (Source: Urologic Oncology)
Source: Urologic Oncology - May 29, 2021 Category: Urology & Nephrology Authors: Arnas Rakauskas Taimur T Shah Max Peters Jagpal S Randeva Feargus Hosking-Jervis Michael J Schmainda Clement Orczyck Mark Emberton Manit Arya Caroline Moore Hashim U Ahmed Source Type: research

Outcomes with brachytherapy based dose escalation for gleason 8 versus 9-10 prostate cancer: An NCDB analysis
CONCLUSION: BT was associated with improved OS when compared to 7560 - 8640 cGy in GS 8, but not in Gleason 9-10 disease. This hypothesis generating study suggests there may be variable benefit with BT in high risk prostate cancer patients on OS. Future prospective studies are needed to investigate whether the benefit of BT is similar across all high risk prostate cancer patients.PMID:34049784 | DOI:10.1016/j.urolonc.2021.04.014 (Source: Urologic Oncology)
Source: Urologic Oncology - May 29, 2021 Category: Urology & Nephrology Authors: John David Michael Luu Diana Lu Zachary S Zumsteg Howard Sandler Mitchell Kamrava Source Type: research

Perioperative optimization of the genitourinary oncology patient
Urol Oncol. 2021 May 25:S1078-1439(21)00178-2. doi: 10.1016/j.urolonc.2021.04.019. Online ahead of print.ABSTRACTRadical cystectomy remains a morbid procedure that is often under-utilized due to its high complication rate. In this seminar we address several interventions to improve the perioperative care of patients undergoing radical cystectomy. These interventions include nutritional support, education and the use of technology. All of the interventions described can be utilized by any center looking to improve the perioperative care of bladder cancer patients.PMID:34049785 | DOI:10.1016/j.urolonc.2021.04.019 (Source: Urologic Oncology)
Source: Urologic Oncology - May 29, 2021 Category: Urology & Nephrology Authors: Jeffrey M Holzbeierlein Source Type: research

Adjuvant versus early salvage radiotherapy for prostate cancer patients: Time to move on
Urol Oncol. 2021 Mar 15:S1078-1439(21)00073-9. doi: 10.1016/j.urolonc.2021.02.012. Online ahead of print.ABSTRACTIn the management of prostate cancer , few treatments have caused as much controversy as adjuvant radiotherapy (ART) after radical prostatectomy in high-risk patients In the present article, we assess the exclusion and inclusion criteria of the 6 randomised trials and 5-year biochemical relapse-free survival and overall survival rates in order to identify the patient subgroups most likely to benefit from ART. We also evaluate treatment-related toxicity and the indications for androgen deprivation therapy . The m...
Source: Urologic Oncology - May 29, 2021 Category: Urology & Nephrology Authors: Carmen Gonz ález-San Segundo Felipe Cou ñago Alfonso G ómez-Iturriaga Source Type: research

Is hypofractionation acceptable for prostate bed radiotherapy?
Urol Oncol. 2021 Feb 23:S1078-1439(21)00060-0. doi: 10.1016/j.urolonc.2021.02.002. Online ahead of print.ABSTRACTApproximately 30% of patients who undergo radical prostatectomy for prostate cancer develop disease progression. The only potentially curative treatment in these patients is postoperative radiotherapy with or without hormonotherapy. One of the standards of care in nonsurgical patients is hypofractionated radiotherapy. However, the current evidence based is insufficient to define the optimal dose and fractionation schedule for postoperative radiotherapy. In this context, the aim of this editorial is to assess the...
Source: Urologic Oncology - May 29, 2021 Category: Urology & Nephrology Authors: Fernando L ópez Campos Gemma Sancho Pardo Xavier Maldonado Pijoan Thomas Zilli Felipe Cou ñago Lorenzo Asunci ón Hervás Morón Source Type: research

Prognostic value of preoperative albumin-to-fibrinogen ratio (AFR) in patients with bladder cancer treated with radical cystectomy
CONCLUSION: Preoperative low AFR is a prognostic biomarker for worse TTP, OS, CSS, and is independently associated with adverse tumor pathological features in BC patients undergoing RC. Our results suggest that especially patients with low AFR may be considered for neoadjuvant treatment.PMID:34049782 | DOI:10.1016/j.urolonc.2021.04.026 (Source: Urologic Oncology)
Source: Urologic Oncology - May 29, 2021 Category: Urology & Nephrology Authors: Francesco Claps Samarpit Rai Maria Carmen Mir Bas W G van Rhijn Giorgio Mazzon Laura Elizabeth Davis Crystal Lynn Valadon Tommaso Silvestri Michele Rizzo Murali Ankem Giovanni Liguori Antonio Celia Carlo Trombetta Nicola Pavan Source Type: research

Can quantitative analysis of multi-parametric MRI independently predict failure of focal salvage HIFU therapy in men with radio-recurrent prostate cancer?
CONCLUSIONS: One pharmacokinetic quantitative parameter based on DCE sequences seems to independently predict failure following focal salvage HIFU for radio-recurrent prostate cancer. This likely relates to the tumor microenvironment producing heat-sinks which counter the heating effect of HIFU. Further validation in larger datasets and evaluating mechanisms to reduce heat-sinks are required.PMID:34049783 | DOI:10.1016/j.urolonc.2021.04.017 (Source: Urologic Oncology)
Source: Urologic Oncology - May 29, 2021 Category: Urology & Nephrology Authors: Arnas Rakauskas Taimur T Shah Max Peters Jagpal S Randeva Feargus Hosking-Jervis Michael J Schmainda Clement Orczyck Mark Emberton Manit Arya Caroline Moore Hashim U Ahmed Source Type: research

Outcomes with brachytherapy based dose escalation for gleason 8 versus 9-10 prostate cancer: An NCDB analysis
CONCLUSION: BT was associated with improved OS when compared to 7560 - 8640 cGy in GS 8, but not in Gleason 9-10 disease. This hypothesis generating study suggests there may be variable benefit with BT in high risk prostate cancer patients on OS. Future prospective studies are needed to investigate whether the benefit of BT is similar across all high risk prostate cancer patients.PMID:34049784 | DOI:10.1016/j.urolonc.2021.04.014 (Source: Urologic Oncology)
Source: Urologic Oncology - May 29, 2021 Category: Urology & Nephrology Authors: John David Michael Luu Diana Lu Zachary S Zumsteg Howard Sandler Mitchell Kamrava Source Type: research

Perioperative optimization of the genitourinary oncology patient
Urol Oncol. 2021 May 25:S1078-1439(21)00178-2. doi: 10.1016/j.urolonc.2021.04.019. Online ahead of print.ABSTRACTRadical cystectomy remains a morbid procedure that is often under-utilized due to its high complication rate. In this seminar we address several interventions to improve the perioperative care of patients undergoing radical cystectomy. These interventions include nutritional support, education and the use of technology. All of the interventions described can be utilized by any center looking to improve the perioperative care of bladder cancer patients.PMID:34049785 | DOI:10.1016/j.urolonc.2021.04.019 (Source: Urologic Oncology)
Source: Urologic Oncology - May 29, 2021 Category: Urology & Nephrology Authors: Jeffrey M Holzbeierlein Source Type: research

Papillary renal cell carcinoma: Review
Urol Oncol. 2021 May 22:S1078-1439(21)00170-8. doi: 10.1016/j.urolonc.2021.04.013. Online ahead of print.ABSTRACTKidney cancer is the 13th most common malignancy globally, and the incidence is rising. Papillary renal cell carcinoma is the second most common subtype, comprising 10-15% of renal cell carcinomas. Though the histologic features of this subtype were initially described in the 1990's, our understanding of the genetic and molecular characteristics of this disease have rapidly evolved over the past decade. In this review, we summarize the contemporary understanding of the clinical, morphologic, radiographic, and ge...
Source: Urologic Oncology - May 26, 2021 Category: Urology & Nephrology Authors: Neil Mendhiratta Peter Muraki Anthony E Sisk Brian Shuch Source Type: research

Papillary renal cell carcinoma: Review
Urol Oncol. 2021 May 22:S1078-1439(21)00170-8. doi: 10.1016/j.urolonc.2021.04.013. Online ahead of print.ABSTRACTKidney cancer is the 13th most common malignancy globally, and the incidence is rising. Papillary renal cell carcinoma is the second most common subtype, comprising 10-15% of renal cell carcinomas. Though the histologic features of this subtype were initially described in the 1990's, our understanding of the genetic and molecular characteristics of this disease have rapidly evolved over the past decade. In this review, we summarize the contemporary understanding of the clinical, morphologic, radiographic, and ge...
Source: Urologic Oncology - May 26, 2021 Category: Urology & Nephrology Authors: Neil Mendhiratta Peter Muraki Anthony E Sisk Brian Shuch Source Type: research

Papillary renal cell carcinoma: Review
Urol Oncol. 2021 May 22:S1078-1439(21)00170-8. doi: 10.1016/j.urolonc.2021.04.013. Online ahead of print.ABSTRACTKidney cancer is the 13th most common malignancy globally, and the incidence is rising. Papillary renal cell carcinoma is the second most common subtype, comprising 10-15% of renal cell carcinomas. Though the histologic features of this subtype were initially described in the 1990's, our understanding of the genetic and molecular characteristics of this disease have rapidly evolved over the past decade. In this review, we summarize the contemporary understanding of the clinical, morphologic, radiographic, and ge...
Source: Urologic Oncology - May 26, 2021 Category: Urology & Nephrology Authors: Neil Mendhiratta Peter Muraki Anthony E Sisk Brian Shuch Source Type: research

Papillary renal cell carcinoma: Review
Urol Oncol. 2021 May 22:S1078-1439(21)00170-8. doi: 10.1016/j.urolonc.2021.04.013. Online ahead of print.ABSTRACTKidney cancer is the 13th most common malignancy globally, and the incidence is rising. Papillary renal cell carcinoma is the second most common subtype, comprising 10-15% of renal cell carcinomas. Though the histologic features of this subtype were initially described in the 1990's, our understanding of the genetic and molecular characteristics of this disease have rapidly evolved over the past decade. In this review, we summarize the contemporary understanding of the clinical, morphologic, radiographic, and ge...
Source: Urologic Oncology - May 26, 2021 Category: Urology & Nephrology Authors: Neil Mendhiratta Peter Muraki Anthony E Sisk Brian Shuch Source Type: research

Artificial intelligence in urological oncology: An update and future applications
Urol Oncol. 2021 May 20:S1078-1439(21)00122-8. doi: 10.1016/j.urolonc.2021.03.012. Online ahead of print.ABSTRACTThere continues to be rapid developments and research in the field of Artificial Intelligence (AI) in Urological Oncology worldwide. In this review we discuss the basics of AI, application of AI per tumour group (Renal, Prostate and Bladder Cancer) and application of AI in Robotic Urological Surgery. We also discuss future applications of AI being developed with the benefits to patients with Urological Oncology.PMID:34024704 | DOI:10.1016/j.urolonc.2021.03.012 (Source: Urologic Oncology)
Source: Urologic Oncology - May 24, 2021 Category: Urology & Nephrology Authors: Andrew Brodie Nick Dai Jeremy Yuen-Chun Teoh Karel Decaestecker Prokar Dasgupta Nikhil Vasdev Source Type: research